Anti-inflammatory and nitric oxide-inhibiting properties of granulocyte colony-stimulating factor

Acta Pharmacologica Sinica

Volumn 20, Issue 8, 1999, Pages 673-681

  Hoffmann, Georg ^a   Schobersberger, Wolfgang ^b  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Cytokines; Granulocyte colony stimulating factor; Infection; Inflammation; Nitric oxide synthase; Sepsis

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; NITRIC OXIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; CELLULAR IMMUNITY; CHROMOSOME 1; CHROMOSOME 17; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; INFECTION; INFLAMMATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; NORMAL HUMAN; RAT; REVIEW; SEPSIS; SUBCUTANEOUS DRUG ADMINISTRATION; VASCULAR SMOOTH MUSCLE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; SEPSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032841187     PISSN: 02539756     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Bradley TR, Metcalf D. The growth of mouse bone marrow cells in vitro. Aust J Exp Biol Med Sci 1966; 44: 287-94.
2. Kanda N, Fukushige S, Murotsu T, Yoshida MC, Tsuchiya M, Asano S, et al. Human gene coding for granulocye cology-stimulating factor is assigned to the q21-q22 region of chromosome 17. Somat Cell Mol Genet 1987; 13: 679-84.
3. Buchberg AM, Bedigian HG, Taylor BA, Brewnell E, Ihle JM, Nagata S, et al. Localization of Evi-2 to chromosome 11: linkage to other proto-oncogene and growth factor loci using interspecific backcross mice. Oncogene Res 1988; 2: 149-65.
4. Nagata S, Tsuchiya M, Asano S, Yamamoto O, Hirata Y, Kubota N, et al. The chromosomal gene structure and two mRNAs for human granulocye cology-stimulating factor. EMBO J 1986; 5: 575-81.
5. Tsuchiya M, Kaziro Y, Nagata S. The chromosomal gene structure for murine granulocyte colony-stimulating factor. Eur J Biochem 1987; 165: 7-12.
6. Vellenga E, Rambaldi A, Ernst TJ, Ostapovicz D, Griffin JD. Independent regulation of M-CSF and G-CSF gene expression in human monocytes. Blood 1988; 71: 1529-32.
7. Lu L, Walker D, Graham CD, Waheed A, Shadduck RK, Broxmeyer HE. Enhancement of release from MHC class II antigen-positive monocytes of hematopoetic colony stimulating factors CSF-1 and G-CSF by recombinant human tumor necrosis factor-α: synergism with recombinant human interferon-γ. Blood 1988; 72: 34-41.
8. Sallerfors B, Olofsson T. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) secretion by adherent monocytes measured by quantitative immunoassays. Eur J Haematol 1992; 49: 199-207.
9. Nelson S. Role of granulocyte colony-stimulating factor in the immune response to acute bacterial infection in the non-neutropenic host: an overview. Clin Infect Dis 1994; 18 Suppl 2: S197-S204.
10. Seelentag WK, Mermod JJ, Montesano R, Vassalli P. Additive effects of interleukin-1 and tumor necrosis factor-α on the accumulation of the three granulocyte and macrophage colony-stimulating factor mRNAs in human endothelial cells. EMBO J 1987; 6: 2261-5.
11. Koeffler HP, Gasson J, Ranyard J, Souza L, Shepard M, Munker R. Recombinant human TNF α stimulates production of granulocyte colony-stimulating factor. Blood 1987; 70: 55-9.
12. Demetri GD, Zenzie BW, Rheinwald JG, Griffin JD. Expression of colony-stimulating factor gene by normal human mesothelial cells and human malignant mesothelioma cell lines in vitro. Blood 1989; 74: 940-6.
13. Lu L, Srour EF, Warren DJ, Walker D, Graham CD, Walker EB, et al. Enhancement of release of granulocyte- and granulocyte-macrophage colony-stimulating factors from phytohemagglutinin-stimulated sorted subsets of human T lymphocytes by recombinant human tumor necrosis factor-α. J Immunol 1988b; 141: 201-7.
14. Nishizawa M, Nagata S. Regulatory elements responsible for inducible expression of the granulocyte colony-stimulating factor gene in macrophages. Mol Cell Biol 1990; 10: 2002-11.
15. Nishizawa M, Tsuchiya M, Watanabe-Fukunaga R, Nagata S. Multiple elements in the promoter of granulocyte colony-stimulating factor gene regulate its constitutive expression in human carcinoma cells. J Biol Chem 1990; 265: 5897-902.
16. Lai CF, Baumann H. Interleukin-1β induces production of granulocyte colony-stimulating factor in human hepatoma cells. Blood 1996; 87: 4143-8.
17. Oheda M, Hase S, Ono M, Ikenaka T. Structures of the sugar chain of recombinant human granulocyte colony-stimulating factor produced by Chinese hamster ovary cells. J Biochem 1988; 103: 544-6.
18. Oheda M, Hasegawa M, Hattori K, Kuboniwa H, Kojima T, Orita T, et al. O-linked sugar chain of human granulocyte colony-stimulating factor protects it against polymerization and denaturation allowing it to retain its biological activity. J Biol Chem 1990; 265: 11432-5.
19. Nissen C, Carbonare VD, Moser Y. In vitro comparison of the biological potency of glycosylated versus nonglycosylated rG-CSF. Drug Invest 1994; 7: 346-52.
20. Inizawa J, Fukunaga R, Seto Y, Nakagawa H, Misawa S, Abe T, et al. Assignment of the human granulocyte colony-stimulating factor receptor gene (CSFR3) to chromosome 1 at region p35-p34.3. Genomics 1991; 10: 1075-8.
21. Ito Y, Seto Y, Brennan CI, Copeland NG, Jenkins NA, Fukunaga R, et al. Structural analysis of the functional gene and pseudogene for the murine granulocyte colony-stimulating factor receptor. Eur J Biochem 1994; 220: 881-91.
22. Rapoport AP, Abboud CN, Di Persio JF. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) receptor biology, signal transduction, and neutrophil activation. Blood Rev 1992; 6: 43-57.
23. Moore MA. The clinical use of colony stimulating factors. Annu Rev Immunol 1991; 9: 159-91.
24. Hanazono Y, Hosoi T, Kuwaki T, Tatsuki S, Miyazono K. Structural analysis of the receptors for granulocyte colony-stimulating factor on neutrophils. Exp Hematol 1990; 18: 1097-103.
25. Tkatch LS, Rubin KA, Ziegler SF, Tweardy DJ. Modulation of human G-CSF receptor mRNA and protein in normal and leukemic myeloid cells by G-CSF and retinoic acid. J Leuk Biol 1995; 57: 964-71.
26. Khwaja A, Carver J, Jones HM, Paterson D, Linch DC. Expression and dynamic modulation of the human granulocyte colony-stimulating factor receptor in immature and differentiated myeloid cells. Br J Haematol 1993; 85: 254-9.
27. 125I-labeled granulocyte colony-stimulating factor to normal murine hemopoietic cells. J Cell Physiol 1985; 124: 313-21.
28. Shimoda K, Okamura S, Harada N, Kondo S, Okamura T, Niho Y. Identification of a functional receptor for granulocyte colony-stimulating factor on platelets. J Clin Invest 1993; 91: 1310-3.
29. Avalos BR, Gasson JC, Hedvat C, Quan SG, Baldwin GC, Weisbart RH, et al. Human granulocyte colony-stimulating factor: biological activities and receptor characterization on hematopoietic cells and small cell lung cancer cell lines. Blood 1990; 75: 851-7.
30. Tidow N, Welte K. Advances in understanding postreceptor signalling in response to granulocyte colony-stimulating factor. Curr Opin Hematol 1997; 4: 171-5.
31. Avalos BR. Molecular analysis of the granulocyte colony-stimulating factor receptor. Blood 1996; 88: 761-77.
32. Dong F, van Buitenen C, Pouwels K, Hoefsloot LH, Löwenberg B, Touw IP. Distinct cytoplasmic region of the human G-CSF receptor involved in transduction of proliferative and maturation signals. Cell Biol 1993; 13: 7774-81.
33. Fukunaga R, Ishizaka-Ikeda E, Nagata S. Growth and differentiation signals mediated by different regions in the cytoplasmic domain of granulocyte colony-stimulating factor receptor. Cell 1993; 74: 1079-87.
34. Nicholson SE, Novak U, Ziegler SF, Layton JE. Distinct regions of the granulocyte colony-stimulating factor receptor are required for tyrosine phosphorylation of the signalling molecules JAK2, STAT3, and p42, p44 MAPK. Blood 1995; 86: 3698-704.
35. Chakraborty A, White SM, Schaefer TS, Ball ED, Dyer KF, Tweardy DJ. Granulocyte colony-stimulating factor activation of STAT3-a and STAT3-b in immature normal and leukemic human myeloid cells. Blood 1996; 88: 2442-9.
36. Bashey A, Healy L, Marshall CJ. Proliferative but not non-proliferative responses to granulocyte colony-stimulating factor are associated with rapid activation of the p21ras/MAP. kinase signalling pathway. Blood 1994; 83: 949-57.
37. Görgen I, Hartung T, Leist M, Niehörster M, Tiegs G, Uhlig S, et al. Granulocyte colony-stimulating factor treatment protects rodents against lipopolysaccharide-induced cytotoxicity via suppression of systemic tumor necrosis factor-α. J Immunol 1992; 149: 918-24.
38. Squadrito F, Altavilla D, Squadrito G, Campo GM, Ioculano M, Ammendiola L, et al. The effects of recombinant human granulocyte colony-stimulating factor on vascular dysfunction and splanchnic ischaemia-reperfusion injury. Br J Pharmacol 1997; 120: 333-9.
39. Villa P, Shaklee CL, Meazza C, Agnello D, Ghezzi P, Senaldi G. Granulocyte colony-stimulating factor and antibiotics in the prophylaxis of a murine model of polymicrobial peritonitis and sepsis. J Infect Dis 1998; 178: 471-7.
40. Lorenz W, Reimund KP, Weitzel F. Granulocyte colony-stimulating factor prophylaxis before operation protects against lethal consequences of postoperative peritonitis. Surgery 1994; 116: 925-34.
41. Freeman BD, Quezado Z, Zeni F, Natanson C, Danner RL, Banks S, et al. rG-CSF reduces endotoxemia and improves survival during E coli pneumonia. J Appl Physiol 1997; 83: 1467-75.
42. Frede S, Deetjen C, Schobersberger W, Hoffmann G. Granulocyte colony-stimulating factor inhibits TNF-α production in a human hepatoma cell line. Pflügers Arch (Eur J Physiol) 1998; 436: 233-7.
43. Hartung T, Döcke WD, Gantner F, Krieger G, Sauer A, Stevens P, et al. Effect of granulocyte colony-stimulating factor treatment on ex vivo blood cytokine response in human volunteers. Blood 1995; 85: 2482-9.
44. Pajkrt D, Manten A, van der Poll T, Tiel-van Buul MMC, Jansen J, Wouter ten Cate J, et al. Modulation of cytokine release and neutrophil function by granulocyte colony-stimulating factor during endotoxemia in humans. Blood 1997; 90: 1415-24.
45. Welte K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G. Filgrastim (r-metHuG-CSF): the first 10 years. Blood 1996; 88: 1907-29.
46. Ishikawa K, Tanaka H, Matsuoka T, Shimazu T, Yoshioka T, Suhimoto H. Recombinant human granulocyte colony-stimulating factor attenuates inflammatory responses in septic patients with neutropenia. J Trauma 1998; 44: 1047-55.
47. Weiss M, Gross-Weege W, Schneider M, Neidhardt H, Liebert S, Mirow N, et al. Enhancement of neutrophil function by in vivo filgrastim treatment for prophylaxis of sepsis in surgical intensive care patients. J Crit Care 1995; 10: 21-6.
48. Weiss M, Gross-Weege W, Harms B, Schneider EM. Filgrastim (rhG-CSF) related modulation of the inflammatory response in patients at risk of sepsis or with sepsis. Cytokine 1996; 8: 260-5.
49. Heard SO, Fink MP, Gamelli RL, Solomkin JS, Joshi M, Trask AL, et al. Effect of prophylactic administration of recombinant human granulocyte colony-stimulating factor (filgrastim) on the frequency of nosokomial infections in patients with acute traumatic brain injury or cerebral hemorrhage. Crit Care Med 1998; 26: 748-54.
50. Nelson S, Belknap S, Carlson W, Dale D, DeBoisblanc B, Farcas S, et al. A randomized controlled trial of filgrastim as an adjunct to antibiotics for treatment of hospitalized patients with community-acquired pneumonia. J Infect Dis 1998; 178: 1075-80.
51. Wright CE, Rees DD, Moncada S. Protective and pathological roles of nitric oxide in endotoxin shock. Cardiovasc Res 1992; 26: 48-57.
52. Hierholzer C, Harbrecht B, Menezes JM, Kane J, MacMicking J, Nathan CF, et al. Essential role of induced nitric oxide in the initiation of the inflammatory response after hemorrhagic shock. J Exp Med 1998; 187: 917-28.
53. Palmer RMJ, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988; 333: 664-6.
54. Förstermann U, Kleinert H. Nitric oxide synthase: expression and expressional control of the three isoforms. Naunyn Schmiederbergs Arch Pharmacol 1995; 352: 351-64.
55. Kilbourn RG, Traber DL, Szabo C. Nitric oxide and shock. Dis Month 1997; 5: 277-348.
56. Hoffmann G, Schobersberger W. Granulocyte colony-stimulating factor inhibits inducible nitric oxide synthase gene expression in pulmonary epithelial cells in vitro. Eur J Pharmacol 1998; 358: 169-76.
57. Deetjen C, Frede S, Smolny M, Seibel M, Schobersberger W, Hoffmann G. Inhibition of inducible nitric oxide synthase gene expression and nitric oxide synthesis in vascular smooth muscle cells by granulocyte colony-stimulating factor. Immunopharmacol (in press).
58. Squadrito F, Altavilla D, Canale P, Ioculano M, Campo GM, Ammendiola L, et al. Participation of tumor necrosis factor and nitric oxide in the mediation of vascular dysfunction in splanchnic artery occlusion shock. Br J Pharmacol 1994; 113: 1153-8.
59. Golab J, Stoklosa T, Zagozdzon R, Kaca A, Giermasz A, Pojda Z, et al. G-CSF prevents the suppression of bone marrow hematopoiesis induced by IL-12 and augments its antitumor activity in a melanoma model in mice. Ann Oncol 1998; 9: 63-9.
60. Golab J, Zagozdzon R, Stoklosa T, Kaca A, Dabrowska A, Giermasz A, et al. Granulocyte colony-stimulating factor demonstrates antitumor activity in melanoma model in mice. Neoplasma 1998; 45: 35-9.